BIOHEART-B Reports 2025 Annual Results: Shareholder Loss Narrows 20.3% to 70.053 Million Yuan

Stock News

03/27

BIOHEART-B (02185) announced its annual results for the period ending December 31, 2025. The company recorded revenue of 44.932 million yuan. The loss attributable to owners of the parent company was 70.053 million yuan, representing a narrowing of 20.3% compared to the previous year. The basic loss per share was 0.29 yuan. The company's revenue for 2025 was generated from the commercialization of its RDN products. Research and development expenses for the 2025 fiscal year were approximately 61.90 million yuan, an increase of 49.9% year-on-year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1112088220"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112088220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112088220?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112088220","market":"nz","top_or_hot":-1,"title":"BIOHEART-B Reports 2025 Annual Results: Shareholder Loss Narrows 20.3% to 70.053 Million Yuan","media":"Stock News","content":"<p>BIOHEART-B (02185) announced its annual results for the period ending December 31, 2025. The company recorded revenue of 44.932 million yuan. The loss attributable to owners of the parent company was 70.053 million yuan, representing a narrowing of 20.3% compared to the previous year. The basic loss per share was 0.29 yuan. The company's revenue for 2025 was generated from the commercialization of its RDN products. Research and development expenses for the 2025 fiscal year were approximately 61.90 million yuan, an increase of 49.9% year-on-year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B Reports 2025 Annual Results: Shareholder Loss Narrows 20.3% to 70.053 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B Reports 2025 Annual Results: Shareholder Loss Narrows 20.3% to 70.053 Million Yuan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-27 00:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BIOHEART-B (02185) announced its annual results for the period ending December 31, 2025. The company recorded revenue of 44.932 million yuan. The loss attributable to owners of the parent company was 70.053 million yuan, representing a narrowing of 20.3% compared to the previous year. The basic loss per share was 0.29 yuan. The company's revenue for 2025 was generated from the commercialization of its RDN products. Research and development expenses for the 2025 fiscal year were approximately 61.90 million yuan, an increase of 49.9% year-on-year.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"醫療保健設備","start_time":0,"source_url":"","article_id":"1112088220","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112088220","pubTimestamp":1774541060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOHEART-B (02185) announced its annual results for the period ending December 31, 2025. The company recorded revenue of 44.932 million yuan. The loss attributable to owners of the parent company was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"translate_title":"BIOHEART-B公布2025年度业绩：股东亏损收窄20.3%至7005.3万元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"BIOHEART-B (02185) announced its annual results for the period ending December 31, 2025. The company recorded revenue of 44.932 million yuan. The loss attributable to owners of the parent company was 70.053 million yuan, representing a narrowing of 20.3% compared to the previous year. The basic loss per share was 0.29 yuan. The company's revenue for 2025 was generated from the commercialization of its RDN products. Research and development expenses for the 2025 fiscal year were approximately 61.90 million yuan, an increase of 49.9% year-on-year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}